Biocon
Update in progressBIOCON.NS (NSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Biocon Limited and its subsidiaries develop, manufacture, and sell biotechnology products and research services in India, the United States, Ireland, the EU, and globally. It operates through Generics, Biosimilars, and Research segments, offering generic formulations and APIs across cardiovascular, diabetes, obesity, MS, anti-fungal, cancer, immunosuppressants, and specialty molecules, plus biosimilars. It provides discovery, development, and manufacturing services for pharma, biotech, animal health, and agro sectors. Incorporated in 1978, headquartered in Bengaluru.
Company score
- Sentiment
- 1.97
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.83
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.79
- Governance
- -0.19
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.78
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.37
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!